ESMO: 50% of patients with advanced NSCLC benefit from excellent survival with up to 4 years of survival degree Vale eu monoantitherapy.

Data from the Phase III PACIFIC trial released at the ESMO Conference also showed that about 35 percent of patients with non-small cell lung cancer did not develop the disease four years after receiving infinity treatment.
39 Health has learned that the latest Phase III PACIFIC clinical trial update results show that AstraZeneve's Infinfan (chemical name: Dovaleyu single anti-Durvalumab, product name: Infinfan Imfinzi) in the receiving of simultaneous release In patients with non-removable non-small cell lung cancer (NSCLC) who did not show disease progression after chemotherapy (CRT), the benefits of continuous and clinically significant total survival (OS) and disease-free progression survival (PFS) were shown.
in China, about one-third of patients with non-small cell lung cancer (NSCLC) are in Stage III at the time of diagnosis, at which point most patients' tumors are no longer removable (cannot be surgically removed).
in the decades leading up to the approval of the Dvaliyu monotherapy, no new treatments appeared for patients other than radiotherapy (CRT).
analysis, which was updated, showed that after chemotherapy, the four-year total survival rate of the dovalyu monotherapy group was about 49.6 percent, compared with 36.3 percent in the placebo group.
total survival (OS) of the 10-degree Valeian monoantigroup and the placebo group were 47.5 months and 29.1 months, respectively.
About 35.3 percent of patients with non-small cell lung cancer who received stage III non-removable stage III non-small cell lung cancer after a maximum of one year of treatment did not develop the disease after four years in the group, up from 19.5 percent in the placebo group.
the New England Journal of Medicine (NEJM) in 2018, the updated data confirm the significant benefits of the Dvaliyu monoantigen in terms of total end-of-life (OS).
Corinne Faivre-Finn, a professor at the University of Manchester and The Christie NHS Foundation Trust and lead researcher on the Phase III PACIFIC trial, said: "In the past, only 15 to 30 per cent of Stage III was unstoppable unless patients with small cell lung cancer survived for five years and most eventually metascised.
the data show that about half of patients who received Dvaliyu monotherapy survived for four years, and about 35 percent did not develop the disease, representing significant progression in clinical healing. "These unprecedented four-year total survival results reinforce the fact that Dvaliu monoantigen is the standard treatment for Phase III inextricable small cell lung cancer, setting new survival goals for clinical cures," said Jose Baselga, Global Executive Vice President, Oncology Research and Development at
AstraZeneta.
, the ESMO Conference also released updated data on CASPIAN studies for patients with small cell lung cancer.
of the degree of valiyu monoantigen continues to bring significant long-term benefits to different types of lung cancer patients.
" major analysis of the total lifetime (OS) of the Phase III PACIFIC trial found that the most common adverse reactions (with a rate equal to or higher than 20%) in the Dvaliyu monoantigen and placebo groups included cough (35.2% vs. 25.2%), fatigue (24.0% vs. 20.5%), breathing difficulties (22.3% vs. 23.9%), and radioactive pneumonia (20.2% vs. 15.8%). 30.5 per cent of patients treated with
degrees of vale euthanrapy experienced level 3 or 4 adverse reactions, while 26.1 per cent of patients in the placebo group were terminated due to adverse reactions, while 15.4 per cent of patients in the dose relief group had terminated treatment due to adverse reactions, while the proportion in the placebo group was 9.8 per cent.
The exploratory subgroup analysis of Phase III CASPIAN clinical studies for patients with extensive stage small cell lung cancer (ES-SCLC) was published at the 2020 European Society of Oncology (ESMO) online annual meeting: a new exploratory subgroup analysis for the Dvaliyu single-resistant CASPIAN III trial aimed at understanding the clinical characteristics of patients who have benefited in the long term. Patients who received a disease-free progression survival of one year or more in the
-degree valeian mono-anti-combination chemotherapy group (PFS of 12 months) were more than three times as likely as those in the pure chemotherapy group, accounting for 17% (the combined chemotherapy group of the valeian mono-anti-combination chemotherapy group) and 4.5% (the chemotherapy-simple group, respectively).
in all treatment queues, patients who had achieved a one-year disease-free progression period were more than 75 percent more likely to survive two years.
, patients who developed the disease in the first year (PFS -lt;12 months) had only a 10 percent chance of surviving two years.
have not yet found any clinical features that can help identify patients who benefit from long-term survival.
patients with PFS of 12 months received more courses of vulliu monoantigen therapy (25 vs 7 in the medium course) than patients with PFS and 12 months.
Although the rate of immuno-mediated adverse reactions was higher in patients who received more degree valiu monotherapy, the rates of severe adverse reactions, severe adverse reactions and drug suspension due to adverse reactions were similar in both subgroups.
THE CASPIAN study reached the end of the total lifetime (OS) study in 2019, and compared to chemotherapy alone, the dose of valiant monotherapy reduced the risk of death in patients with broad-stage small cell lung cancer by 27 percent.
the safety and toeration of 100-degree vale euthanrapy is consistent with the known safety of these drugs.
the findings, which were published in The Lancet in 2019, are based on the fact that global regulators have approved the listing of the Dvaliyu monolith.
results of the phase III trials of 7PACIFIC and CASPIAN were announced at the 2020 ESMO Online Annual Meeting held from September 19 to 21.
lung cancer is the leading cause of cancer deaths in both men and women, accounting for about one-fifth of all cancer deaths.
generally, lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC);
according to the local metastasis range of cancer cells and whether surgery can be performed, Phase III (local progress) non-small cell lung cancer (NSCLC) is usually divided into three types: IIIA, IIIB, and IIIC.
the distant metastasis that has occurred in patients with stage IV lung cancer, most patients with stage III non-small cell lung cancer have the potential for clinical cure.
in 2015, there were 200,000 cases of stage III non-small cell lung cancer in China, France, Germany, Italy, Japan, Spain, the United Kingdom and the United States, and 43,000 in the United States alone.
small cell lung cancer (SCLC) is an aggressive and rapidly growing lung cancer that responds well initially to chemotherapy drugs, but still relapses and deteriorates rapidly.
about two-thirds of patients with small cell lung cancer are diagnosed at a widespread stage, and cancer cells have spread in the lungs or transferred to other tissues or organs of the body.
of small cell lung cancer is poor, with a five-year survival rate of only about 6%.
About PACIFIC Research PACIFIC is a randomized, double-blind, placebo-controlled international multi-center Phase III clinical trial designed to assess the efficacy of all non-removable Stage III (local progression) non-small cell lung cancer patients who did not progress after platinum-based synchronous radiotherapy.
clinical trial was conducted in 235 centers in 26 countries around the world, recruiting a total of 713 patients.
the main research endpoints are disease-free progression lifetime (PFS) and total survival (OS), and the secondary study endpoints are PFS and OS boundary analysis, objective mitigation rate and mitigation duration.
the CASPIAN Study CASPIAN Study is a randomized, open-labeled global multi-center Phase III clinical trial in a group of 805 patients with extensive stage small cell lung cancer treated with first-line treatment.
the trial compared the combined standard chemotherapy (espressoside plus cisplatin or carabin), the polyvalliu monoanti-tremelimumab (anti-CTL4 antibody), and the chemotherapy group, as well as the individual chemotherapy.
in the trial group, the patient underwent four cycles of chemotherapy.
in the control group, patients received up to 6 cycles of chemotherapy, and intracranial preventive radiotherapy was selected according to the situation.
trial was conducted at more than 200 medical centers in 23 countries around the world, including the United States, Europe, South America, Asia and the Middle East.
the main end point of this clinical trial is total lifetime.
June 2019, AstraZenecom announced that a predetermined mid-term analysis of the CASPIAN trial showed that the dovaliu mono-combination chemotherapy had reached the primary endpoint of total lifetime (OS).
March 2020, the company announced that the combined treatment group for tremelimumab had not reached the main endpoint of its total lifetime (OS).
about Infineon (Duvalvalumab) is a human-sourced PD-L1 monoclonal antibody that blocks the binding of PD-L1 to PD-1 and CD80, thereby blocking tumor immune escape and releasing suppressed immune responses.
based on PACIFIC clinical trial data, Infineon has been approved in the United States, Japan, China, the European Union and many other countries for phase III non-necessary treatment after chemotherapy for small cell lung cancer.
has also been approved in the United States and several other countries for the treatment of advanced bladder cancer.
addition, Dvaliyu monoantigen has been approved for treatment in patients with extensive stage small cell lung cancer in the United States, the European Union, Japan and other countries.
As part of a new drug development project, Dvaliyu monoantigen is currently exploring therapeutic prospects in the form of individual drugs or in the form of combined CTLA-4 antibody tremelimumab and other new drugs in the direction of non-small cell lung cancer, small cell lung cancer, bladder cancer, head and neck cancer, liver cancer, bile duct cancer, cervical cancer, endometrial cancer and other solid tumors.
39 Health.com Source: 39 Health.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.